Present and prospective clinical therapeutic regimens for Alzheimer’s disease

Mustafa M Husain, Kenneth Trevino, Haroon Siddique, Shawn M McClintockDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increas...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mustafa M Husain, Kenneth Trevino, Haroon Siddique, Shawn M McClintock
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/8a88292fbcab4c83aab17d0eff998c9f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8a88292fbcab4c83aab17d0eff998c9f
record_format dspace
spelling oai:doaj.org-article:8a88292fbcab4c83aab17d0eff998c9f2021-12-02T08:25:03ZPresent and prospective clinical therapeutic regimens for Alzheimer’s disease1176-63281178-2021https://doaj.org/article/8a88292fbcab4c83aab17d0eff998c9f2008-09-01T00:00:00Zhttp://www.dovepress.com/present-and-prospective-clinical-therapeutic-regimens-for-alzheimerrsq-a2202https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Mustafa M Husain, Kenneth Trevino, Haroon Siddique, Shawn M McClintockDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increase in severity as the disease progresses. The clinical symptoms are related to the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of the disease can result in clinical burden for the patient, emotional strain for those that care for patients with Alzheimer’s, and significant financial burden to society. The goals of current treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to reduce the severity or slow the progression of cognitive symptoms. Although these treatments have demonstrated modest clinical benefit, they are unable to prevent, prohibit, or reverse the underlying pathophysiology of AD. Considerable progress has been made toward the development of disease-modifying treatments. Treatments currently under development mainly target the production, aggregation, and removal of existing amyloid β-peptide aggregates which are believed to instigate the overall development of the neuropathology. Additional strategies that target tau pathology are being studied to promote neural protection against AD pathology. The current research has continued to expand our knowledge toward the development of disease modifying Alzheimer’s therapies; however, no specific treatment strategy capable of demonstrating empirical efficacy and safety has yet to emerge.Keywords: Alzheimer’s disease, disease-modifying therapies, current treatments, pathophysiology Mustafa M HusainKenneth TrevinoHaroon SiddiqueShawn M McClintockDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 4, Pp 765-777 (2008)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Mustafa M Husain
Kenneth Trevino
Haroon Siddique
Shawn M McClintock
Present and prospective clinical therapeutic regimens for Alzheimer’s disease
description Mustafa M Husain, Kenneth Trevino, Haroon Siddique, Shawn M McClintockDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USAAbstract: Alzheimer’s disease (AD) is an incurable neurodegenerative disorder that produces cognitive impairments that increase in severity as the disease progresses. The clinical symptoms are related to the presence of neuritic plaques and neurofibrillary tangles in the cerebral cortex which represent the pathophysiological hallmarks of AD. The debilitating nature of the disease can result in clinical burden for the patient, emotional strain for those that care for patients with Alzheimer’s, and significant financial burden to society. The goals of current treatments, such as cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonist, are to reduce the severity or slow the progression of cognitive symptoms. Although these treatments have demonstrated modest clinical benefit, they are unable to prevent, prohibit, or reverse the underlying pathophysiology of AD. Considerable progress has been made toward the development of disease-modifying treatments. Treatments currently under development mainly target the production, aggregation, and removal of existing amyloid β-peptide aggregates which are believed to instigate the overall development of the neuropathology. Additional strategies that target tau pathology are being studied to promote neural protection against AD pathology. The current research has continued to expand our knowledge toward the development of disease modifying Alzheimer’s therapies; however, no specific treatment strategy capable of demonstrating empirical efficacy and safety has yet to emerge.Keywords: Alzheimer’s disease, disease-modifying therapies, current treatments, pathophysiology
format article
author Mustafa M Husain
Kenneth Trevino
Haroon Siddique
Shawn M McClintock
author_facet Mustafa M Husain
Kenneth Trevino
Haroon Siddique
Shawn M McClintock
author_sort Mustafa M Husain
title Present and prospective clinical therapeutic regimens for Alzheimer’s disease
title_short Present and prospective clinical therapeutic regimens for Alzheimer’s disease
title_full Present and prospective clinical therapeutic regimens for Alzheimer’s disease
title_fullStr Present and prospective clinical therapeutic regimens for Alzheimer’s disease
title_full_unstemmed Present and prospective clinical therapeutic regimens for Alzheimer’s disease
title_sort present and prospective clinical therapeutic regimens for alzheimer’s disease
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/8a88292fbcab4c83aab17d0eff998c9f
work_keys_str_mv AT mustafamhusain presentandprospectiveclinicaltherapeuticregimensforalzheimeramprsquosdisease
AT kennethtrevino presentandprospectiveclinicaltherapeuticregimensforalzheimeramprsquosdisease
AT haroonsiddique presentandprospectiveclinicaltherapeuticregimensforalzheimeramprsquosdisease
AT shawnmmcclintock presentandprospectiveclinicaltherapeuticregimensforalzheimeramprsquosdisease
_version_ 1718398554379124736